Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Annals of Clinical and Translational Neurology
|
April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy
Daniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Annals of Neurology
|
July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder
Daniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Brain Communications
|
March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Lana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein Aggregates
Lana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
The Lancet. Neurology
|
January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni, Lana M Chahine, Kathleen Poston, et al.
NPJ Parkinson'S Disease
|
September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
Tien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts
Tien Dam, Gennaro Pagano, Michael C Brumm, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Annals of Clinical and Translational Neurology
|
April 22, 2026
Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker-Defined Synucleinopathy
Daniel Weintraub, Michele K York, Roseanne Dobkin, et al.
Annals of Neurology
|
July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder
Daniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Brain Communications
|
March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Lana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein Aggregates
Lana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
The Lancet. Neurology
|
January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni, Lana M Chahine, Kathleen Poston, et al.
NPJ Parkinson'S Disease
|
September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts
Tien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts
Tien Dam, Gennaro Pagano, Michael C Brumm, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 5